Proteins

Product Data Sheet

XMD8-87

Cat. No.: HY-15811 CAS No.: 1234480-46-6 Molecular Formula: $C_{24}H_{27}N_{7}O_{2}$ Molecular Weight: 445.52 Target: Tyrosinase

Pathway: Metabolic Enzyme/Protease

Storage: Powder -20°C 3 years

 $4^{\circ}C$ 2 years

In solvent -80°C 2 years

> -20°C 1 year

NH N N N N N N N N N N N N N N N N N N
--

SOLVENT & SOLUBILITY

In Vitro DMSO : ≥ 26 mg/mL (58.36 mM)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg
	1 mM	2.2446 mL	11.2228 mL	22.4457 mL
	5 mM	0.4489 mL	2.2446 mL	4.4891 mL
	10 mM	0.2245 mL	1.1223 mL	2.2446 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.08 mg/mL (4.67 mM); Clear solution
- 2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE- β -CD in saline) Solubility: 2.08 mg/mL (4.67 mM); Suspended solution; Need ultrasonic

BIOLOGICAL ACTIVITY

Description	$ XMD8-87 is a potent TNK2 inhibitor with IC_{50} values of 38 and 113 nM for the D163E and R806Q mutations, respectively. \\$
IC ₅₀ & Target	IC50: 38 nM (TNK2, D163E mutation), 113 nM (TNK2, R806Q mutation) ^[1]
In Vitro	XMD8-87 potently inhibits the growth of the TNK2 mutant expressing cell lines while having little or no effect on the control cells out to the highest tested concentrations (1,000 nM). XMD8-87 has IC_{50} s of 38 nM and 113 nM for the D163E and R806Q mutations. The effects of XMD8-87 on TNK2 cell lines are largely due to on-target effects on TNK2. Auto-phosphorylation of overexpressed TNK2 mutants could be blocked with TNK2 inhibitor XMD8-87 ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Kinase Assay ^[1] Kinase targets are tested with biochemical enzymatic kinase assays using the SelectScreen Kinase Profiling Service to determine IC₅₀ values. The compounds (XMD8-87) are assayed at 10 concentrations (3-fold serial dilutions starting from 1 μ M) at an ATP concentration equal to the ATP Km^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cells are treated with the following inhibitors for 72 hours: dasatinib, AIM-100, XMD8-87 and XMD16-5. Cell viability is measured using a methanethiosulfonate (MTS)-based assay and absorbance (490 nm) is read at 1 and 3 hours after adding reagent^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Maxson JE, et al. Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic Analysis.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA